Novel Approaches Across Non-Hodgkin Lymphoma Subtypes Demonstrate Continued Benefit
Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.
Related Articles
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.
Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer
Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.
ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC
Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.
KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma
Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.
Luspatercept Increases Likelihood of Lasting Transfusion Independence in ESA-Naive, Lower-Risk MDS
Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.
Adding Zilovertamab Vedotin to Standard Care Shows Strong ORR for DLBCL
Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.
Long-Term Data Underscore Role of Zanubrutinib in Treatment-Naive CLL/SLL With 17p Deletions
Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.
Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC
Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.
T-DXd Rechallenge Is Safe After Grade 1 ILD in Breast Cancer and Other Solid Tumors
A high rate of patients with breast cancer and other solid tumors were rechallenged with trastuzumab deruxtecan after grade 1 interstitial lung disease.